SIGNIFICANCE STATEMENT: Most patients with anti-glomerular basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than half develop ESKD. Currently, no tools are available to aid in the prognostication or management of this rare disease. In one of the largest assembled cohorts of patients with anti-GBM disease (with 174 patients included in the final analysis), the authors demonstrated that the renal risk score for ANCA-associated vasculitis is transferable to anti-GBM disease and the renal histology is strongly predictive of renal survival and recovery. Stratifying patients according to the percentage of normal glomeruli in the kidney biopsy and the need for RRT at the time of diagnosis improves outcome prediction. Such stratification may assist in the management of anti-GBM disease. BACKGROUND: Prospective randomized trials investigating treatments and outcomes in anti-glomerular basement membrane (anti-GBM) disease are sparse, and validated tools to aid prognostication or management are lacking. METHODS: In a retrospective, multicenter, international cohort study, we investigated clinical and histologic parameters predicting kidney outcome and sought to identify patients who benefit from rescue immunosuppressive therapy. We also explored applying the concept of the renal risk score (RRS), currently used to predict renal outcomes in ANCA-associated vasculitis, to anti-GBM disease. RESULTS: The final analysis included 174 patients (out of a total of 191). Using Cox and Kaplan-Meier methods, we found that the RRS was a strong predictor for ESKD. The 36-month renal survival was 100%, 62.4%, and 20.7% in the low-risk, moderate-risk, and high-risk groups, respectively. The need for renal replacement therapy (RRT) at diagnosis and the percentage of normal glomeruli in the biopsy were independent predictors of ESKD. The best predictor for renal recovery was the percentage of normal glomeruli, with a cut point of 10% normal glomeruli providing good stratification. A model with the predictors RRT and normal glomeruli ( N ) achieved superior discrimination for significant differences in renal survival. Dividing patients into four risk groups led to a 36-month renal survival of 96.4% (no RRT, N ≥10%), 74.0% (no RRT, N <10%), 42.3% (RRT, N ≥10%), and 14.1% (RRT, N <10%), respectively. CONCLUSIONS: These findings demonstrate that the RRS concept is transferrable to anti-GBM disease. Stratifying patients according to the need for RRT at diagnosis and renal histology improves prediction, highlighting the importance of normal glomeruli. Such stratification may assist in the management of anti-GBM disease. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_02_27_JASN0000000000000060.mp3.

1st Faculty of Medicine Charles University Prague Czech Republic

Centre for Biostatistics Division of Population Health Health Services Research and Primary Care University of Manchester Manchester United Kingdom

Centre of Clinical and Transplant Pathology Institute of Clinical and Experimental Medicine Prague Czech Republic

Department of Immunology and Inflammation Imperial College London London United Kingdom

Department of Medicine John Hopkins University Baltimore Maryland

Department of Nephrology General University Hospital Prague Czech Republic

Division of Cardiovascular Sciences School of Medical Sciences University of Manchester Manchester United Kingdom

Irish Centre for Vascular Biology Dublin Ireland

Manchester Academic Health Science Centre Research and Innovation Manchester University NHS Foundation Trust Manchester United Kingdom

Renal Department Royal Preston Hospital Lancashire Teaching Hospitals NHS Foundation Trust Preston United Kingdom

Renal Department Salford Royal Hospital Northern Care Alliance NHS Foundation Trust Salford United Kingdom

Renal Pathology Adult Histopathology Unit Manchester University NHS Foundation Trust Manchester United Kingdom

Renal Urology and Transplantation Unit Manchester University NHS Foundation Trust Manchester United Kingdom

Trinity Health Kidney Centre Trinity Translational Medicine Institute Trinity College Dublin Dublin Ireland

J Am Soc Nephrol. 2023 Mar 1;34(3):361-362. doi: 10.1681/ASN.0000000000000069. PubMed

Zobrazit více v PubMed

Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999;10(11):2446-2453. doi:10.1681/ASN.V10112446 PubMed DOI

McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. doi:10.2215/CJN.01380217 PubMed DOI PMC

Tang W, McDonald SP, Hawley CM, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 2013;83(3):503-510. doi:10.1038/ki.2012.375 PubMed DOI

Peto P, Salama AD. Update on antiglomerular basement membrane disease. Curr Opin Rheumatol. 2011;23(1):32-37. doi:10.1097/bor.0b013e328341009f PubMed DOI

Zhao J, Cui Z, Yang R, Jia XY, Zhang Y, Zhao MH. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int. 2009;76(10):1108-1115. doi:10.1038/ki.2009.348 PubMed DOI

Coche S, Sprangers B, Van Laecke S, et al. Recurrence and outcome of anti−glomerular basement membrane glomerulonephritis after kidney transplantation. Kidney Int Rep. 2021;6(7):1888-1894. doi:10.1016/j.ekir.2021.04.011 PubMed DOI PMC

van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63-72. doi:10.2215/CJN.04290417 PubMed DOI PMC

Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535-1540. doi:10.1111/j.1523-1755.2004.00917.x PubMed DOI

McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693-702. doi:10.1016/j.kint.2017.03.014 PubMed DOI PMC

Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30(5):814-821. doi:10.1093/ndt/gfu399 PubMed DOI

Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021 PubMed DOI

Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897-908. doi:10.1016/j.kint.2016.02.001 PubMed DOI

Marques C, Carvelli J, Biard L, et al. Prognostic factors in anti-glomerular basement membrane disease: a multicenter study of 119 patients. Front Immunol. 2019;10:1665. doi:10.3389/fimmu.2019.01665 PubMed DOI PMC

Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37(3):965-970. doi:10.1038/ki.1990.72 PubMed DOI

Wahls TL, Bonsib SM, Schuster VL. Coexistent Wegener’s granulomatosis and anti-glomerular basement membrane disease. Hum Pathol. 1987;18(2):202-205. doi:10.1016/S0046-8177(87)80340-4 PubMed DOI

Bosch X, Mirapeix E, Font J, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol. 1991;36(3):107-113. PubMed

Mörtzell Henriksson M, Weiner M, Sperker W, et al. Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic antibody-associated (ANCA) vasculitis treated with or without therapeutic apheresis. Transfus Apher Sci. 2021;60(6):103227. doi:10.1016/j.transci.2021.103227 PubMed DOI

Philip R, Dumont A, Martin Silva N, de Boysson H, Aouba A, Deshayes S. ANCA and anti-glomerular basement membrane double-positive patients: a systematic review of the literature. Autoimmun Rev. 2021;20(9):102885. doi:10.1016/j.autrev.2021.102885 PubMed DOI

Brix SR, Noriega M, Tennstedt P, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177-1188. doi:10.1016/j.kint.2018.07.020 PubMed DOI

Brix SR, Geetha D. Keeping up with the times: prognostic tools in ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(8):1078-1080. doi:10.2215/CJN.09600620 PubMed DOI PMC

Xia M, Yu R, Zheng Z, et al. Meta-analytical accuracy of ANCA renal risk score for prediction of renal outcome in patients with ANCA-associated glomerulonephritis. Front Med. 2021;8:736754. doi:10.3389/fmed.2021.736754 PubMed DOI PMC

Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006 PubMed DOI PMC

Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594. doi:10.1136/bmj.g7594 PubMed DOI

Soveri I, Mölne J, Uhlin F, et al. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019;96(5):1234-1238. doi:10.1016/j.kint.2019.06.019 PubMed DOI

Uhlin F, Szpirt W, Kronbichler A, et al. Endopeptidase cleavage of anti-glomerular basement membrane antibodies in vivo in severe kidney disease: an open-label phase 2a study. J Am Soc Nephrol. 2022;33(4):829-838. doi:10.1681/ASN.2021111460 PubMed DOI PMC